“Opdivo (nivolumab) 240mg/24ml” has been added to your cart. View cart

Danyelza (naxitamab-gqgk) 40mg

$1,000.00

Danyelza is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response

Category: Cancer Medication Tag: Injectable

Description
Reviews (0)

Description

Danyelza (naxitamab-gqgk) is a monoclonal antibody used to treat high-risk neuroblastoma, a type of cancer that forms in nerve tissue, primarily affecting children. It works by targeting the GD2 antigen found on neuroblastoma cells, helping the immune system recognize and destroy these cancer cells. Danyelza is usually given in combination with GM-CSF (granulocyte-macrophage colony-stimulating factor) to enhance its effectiveness.